全文获取类型
收费全文 | 205426篇 |
免费 | 28212篇 |
国内免费 | 7011篇 |
专业分类
耳鼻咽喉 | 1703篇 |
儿科学 | 1558篇 |
妇产科学 | 5162篇 |
基础医学 | 14826篇 |
口腔科学 | 2161篇 |
临床医学 | 16525篇 |
内科学 | 19603篇 |
皮肤病学 | 1365篇 |
神经病学 | 742篇 |
特种医学 | 5938篇 |
外国民族医学 | 253篇 |
外科学 | 28837篇 |
综合类 | 26000篇 |
现状与发展 | 38篇 |
一般理论 | 3篇 |
预防医学 | 10165篇 |
眼科学 | 121篇 |
药学 | 14544篇 |
138篇 | |
中国医学 | 4975篇 |
肿瘤学 | 85992篇 |
出版年
2024年 | 697篇 |
2023年 | 4472篇 |
2022年 | 8733篇 |
2021年 | 11347篇 |
2020年 | 10576篇 |
2019年 | 9497篇 |
2018年 | 9138篇 |
2017年 | 9537篇 |
2016年 | 10215篇 |
2015年 | 11918篇 |
2014年 | 16991篇 |
2013年 | 16805篇 |
2012年 | 13449篇 |
2011年 | 13616篇 |
2010年 | 9870篇 |
2009年 | 10084篇 |
2008年 | 10346篇 |
2007年 | 9621篇 |
2006年 | 8499篇 |
2005年 | 6913篇 |
2004年 | 5741篇 |
2003年 | 4754篇 |
2002年 | 4022篇 |
2001年 | 3682篇 |
2000年 | 3061篇 |
1999年 | 2598篇 |
1998年 | 2168篇 |
1997年 | 1920篇 |
1996年 | 1540篇 |
1995年 | 1449篇 |
1994年 | 1186篇 |
1993年 | 915篇 |
1992年 | 790篇 |
1991年 | 723篇 |
1990年 | 534篇 |
1989年 | 493篇 |
1988年 | 407篇 |
1987年 | 358篇 |
1986年 | 271篇 |
1985年 | 358篇 |
1984年 | 292篇 |
1983年 | 192篇 |
1982年 | 197篇 |
1981年 | 181篇 |
1980年 | 158篇 |
1979年 | 106篇 |
1978年 | 69篇 |
1977年 | 56篇 |
1976年 | 50篇 |
1975年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
Summary Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer. The dose of dipyridamole was fixed at 175 mg/m2 by mouth every 6 h (700 mg/m2/day), based upon a previous phase I trial of oral dipyridamole with 5-FU and leukovorin. Dipyridamole therapy began 24 h prior to the first dose of chemotherapy and continued until 24 h after the last dose of chemotherapy for each course of treatment. At the initial dose level, leukovorin 200 mg/m2 was given intravenously immediately prior to 5-FU 375 mg/ m2 intravenously on days 1–5. Mitoxantrone 6 mg/m2 was given as a single dose on day 3. Unacceptable toxicity was observed at this dose level, leading to successive dose decrements rather than dose increments. The maximum tolerated dose was leukovorin 200 mg/m2 days 1–2, 5-FU 375 mg/m2 days 1–2, mitoxantrone 6 mg/m2 on day 2, and dipyridamole 175 mg/m2 every 6 h on days 0–3. Two responses were produced in 15 patients. This regimen is not recommended for further investigation in the treatment of breast cancer. 相似文献
102.
Summary The present study provides information relevant to a number of variables which may influence response to treatment of nude mouse-grown human urothelial cancer. A number of xenotransplanted tumors were exposed to selected treatments at different transplant generations, and at various dose levels and treatment schedules. It was observed that nude mouse-grown tumors were characterized by consistency, reproducibility and biological stability not affected by the transplant generation at which they were examined. Treatment related dose response curves were steep, the sharpness of the curves depending on the degree of tumor sensitivity. Best therapeutic results were obtained at the maximum tolerated dose of cytotoxic agents under study and of importance, a 20% to 40% dose reduction with the same treatment schedule resulted in little or no activity. In addition, treatment schedule, timing and sequence of treatments and to a certain degree, tumor grade were important variables which could influence tumor response. The nude mouse-human tumor system provides important preclinical guidelines on dose, schedule, sequence and timing of treatments and can assist in designing more efficient clinical trials. 相似文献
103.
目的 :介绍食管钡餐连续摄影用于诊断早期食管癌的初步临床应用。方法 :用德国产的数字化胃肠机检查并诊断了 6例早期食管癌病人。与常规食管双重对比造影类似 ,病人立位口服钡剂 ,同时进行连续摄影 ,速度为 2帧 s,持续约 10s。观察不同的时相 ,包括充盈相、黏膜相和双对比相。结果 :在 6例病人中可见食管功能的改变及黏膜皱襞的病变 ,用连续摄影诊断后经内镜及病理检查确诊。 4例病人有轻度扩张受限 ,2例病人有痉挛性收缩 ,1例有钡剂滞留。 6例病人中均可见增粗的或中断的黏膜。 5例病人可见小溃疡。结论 :食管钡餐连续摄影可提供更全面的信息。用此法更可提供食管功能性的改变。 相似文献
104.
目的:探讨子宫内膜增生性病变与子宫内膜癌的超声鉴别诊断及内膜癌肌浸程度的估价.方法:采用术前B超、术后大体标本观察测量,对123例子宫内膜病变患者的声像图资料进行分析并与手术后病理结果对照.结果:①子宫内膜病变者子宫三径之和平均值均大于正常值;②58.6%的子宫内膜增生过长病变患者内膜形态以条形、梭形和正常形态回声;35%的Ⅱ期以上子宫内膜癌患者内膜回声以积液为主兼有其它图像类型;③大于50岁患者不同病理类型病变的子宫内膜平均厚度均超过其正常内膜厚度值,但无明显的规律性.小于50岁的患者内膜增厚主要以子宫内膜增生过长病变为主占48%;④通过超声测量子宫内膜厚度判断子宫内膜癌浅肌层和深肌层浸润符合率均为71.4%.结论:超声检查对判断子宫内膜病变病理类型有一定帮助,内膜厚度、内膜形态、回声特点、及内膜与肌层间的关系等,仅提示病变存在的可能性,要鉴别病变的良恶性、肌层浸润深度,须根据上述回声特点进行综合分析. 相似文献
105.
目的 观察PCEA用于肺癌术后的镇痛效果。方法 60例肺癌术后患随机等分为两组:A组采用PCEA,B组肌注镇痛剂。定时监测两组MAP、HR、SpO2、VAS评分、镇静评分及不良反应等。结果 A组镇痛确切,呼吸、循环平稳,患平静合作休息好。结论 PCEA用于肺癌术后镇痛效果好,不良反应少,患满意度高。 相似文献
106.
聂树涛 《中国医师进修杂志》2007,30(10):33-35,49
目的用药物敏感试验预测肺癌合并恶性胸腔积液癌细胞对顺铂联合其他药物的敏感度,观察其在指导此类患者的顺铂联合其他化疗药物胸腔内化疗的价值。方法将44例胸腔积液癌细胞阳性肺癌患者随机分为两组:药物敏感试验组(20例,有2例因体外药物敏感试验失败而被排除)和对照组(22例)。药物敏感试验组患者用三磷酸腺苷-肿瘤细胞药物敏感试验(ATP-TCA)法分别检测胸腔积液癌细胞对顺铂加香菇多糖、顺铂加甘露聚糖肽、顺铂加A群链球菌制剂、顺铂加干扰素、顺铂加金黄色葡萄球菌滤液制剂、顺铂加卡介苗多糖核酸、顺铂加红色诺卡菌细胞壁骨架、顺铂加白细胞介素-2的敏感度,并选择抑瘤率最高的联合化疗药物对患者进行胸腔内化疗,观察治疗后胸腔积液完全缓解率及胸腔积液癌细胞转阴率,并与对照组比较。结果药物敏感试验组患者对各联合化疗药物敏感的例数为:顺铂加香菇多糖14例、顺铂加甘露聚糖肽18例、顺铂加A群链球菌制剂17例、顺铂加干扰素10例、顺铂加金黄色葡萄球菌滤液制剂16例、顺铂加卡介苗多糖核酸15例、顺铂加红色诺卡菌细胞壁骨架17例、顺铂加白细胞介素-216例。药物敏感试验组完全缓解率为65.0%,对照组为27.3%(P〈0.05)。药物敏感试验组胸腔积液癌细胞转阴率为80.0%,对照组为45.5%(P〈0.05)。结论用药物敏感试验指导肺癌合并恶性胸腔积液的胸腔内个体化化疗可提高完全缓解率和胸腔积液癌细胞转阴率,该方法具有临床实用价值。 相似文献
107.
108.
109.
OBJECTIVE: Many patients with haemorrhoids are investigated because of the fear of missing colorectal cancer (CRC). The aim of this study was to determine whether a primarily clinical approach regarding the need for investigation was safe and did not miss patients with CRC. PATIENTS AND METHODS: Data was collected prospectively on 589 consecutive patients with the principle diagnosis of haemorrhoids at first clinic visit. All had clinical assessment including rigid sigmoidoscopy and were treated by phenol injection or banding. They were categorized for (1) no review unless symptoms persisted -'One Stop SOS' (2) outpatient review or (3) investigation. To check for the development of CRC they were contacted by postal questionnaire or telephone interview with a minimum of one year from diagnosis and treatment. All 589 patients were cross-referenced with the Pathology database and the Hospital Information Services System. RESULTS: Four hundred and sixty-nine (80%) answered the questionnaire; 352 patients (60% of the total group) fell in the 'one stop SOS' outpatient category; 95 (16%) patients were followed up to review response to treatment for large haemorrhoids; 105 (18%) were investigated with barium enema (12%), flexible sigmoidoscopy (4%), colonoscopy (1%) and miscellaneous (1%); 37 (6%) patients were either given a haemorrhoidectomy date or referred on with a different diagnosis. No patients selected for 'one-stop' treatment developed CRC. Five (0.8%) patients were diagnosed with CRC after appropriate investigation was instituted for suspicious symptoms. One patient with distal transverse colon cancer had a delayed diagnosis as she was investigated initially by flexible sigmoidoscopy. CONCLUSION: Most patients with the primary diagnosis of symptomatic haemorrhoids do not need investigation. 相似文献
110.
SHILLA CHATTERJEE EUN SUNG PARK MELVYN S. SOLOFF 《International journal of urology》2004,11(10):876-884
BACKGROUND: Insulin-like growth factor binding protein-2 (IGFBP-2) is expressed by all human prostate cancer cell lines and dramatically increases in the serum of prostate cancer patients. However, the role of IGFBP-2 in prostatic tumorigenesis is not known. The aim of the present study was to investigate the effects of IGFBP-2 on the proliferation of DU145 human prostate cancer cells in culture. METHODS: Using cell proliferation assays, we examined the effects of exogenously administered and endogenously modulated levels of IGFBP-2 on the proliferation of DU145 cells. RESULT: Cell growth was stimulated by exogenously administered IGFBP-2, but significantly retarded (P < 0.05) by its neutralizing antibody. Overexpression of IGFBP-2 by transfection also stimulated cell growth, which was significantly (P < 0.05) inhibited in transfectants expressing antisense mRNA to IGFBP-2. Furthermore, the proliferation of IGFBP-2 overexpressing cells was significantly dampened by exogenously administered IGFBP-2 antibody. CONCLUSIONS: IGFBP-2 is an autocrine growth factor for DU145 human prostate cancer cells and cell proliferation can be significantly retarded by neutralizing or inhibiting its synthesis. These findings provide a strong rationale for targeting IGFBP-2 in the testing of novel strategies to treat prostate cancer. 相似文献